KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Gains from Investment Securities: 2017-2025

Historic Gains from Investment Securities for Twist Bioscience (TWST) over the last 7 years, with Sep 2025 value amounting to -$240,000.

  • Twist Bioscience's Gains from Investment Securities was N/A to -$240,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year change of. This contributed to the annual value of -$2.2 million for FY2025, which is 95.10% up from last year.
  • Per Twist Bioscience's latest filing, its Gains from Investment Securities stood at -$240,000 for Q3 2025, which was up 79.17% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Twist Bioscience's Gains from Investment Securities registered a high of $33.5 million during Q2 2021, and its lowest value of -$44.1 million during Q2 2024.
  • Its 3-year average for Gains from Investment Securities is -$5.3 million, with a median of -$595,500 in 2023.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first spiked by 151,083.33% in 2022, then tumbled by 914.13% in 2024.
  • Twist Bioscience's Gains from Investment Securities (Quarterly) stood at $10.4 million in 2021, then slumped by 104.79% to -$499,000 in 2022, then soared by 37.47% to -$312,000 in 2023, then skyrocketed by 214.10% to $356,000 in 2024, then spiked by 97.39% to -$240,000 in 2025.
  • Its Gains from Investment Securities was -$240,000 in Q3 2025, compared to -$1.2 million in Q2 2025 and -$1.2 million in Q1 2025.